Updated: June 1, 2021 9:06:59 am
In a study published in Nature Medicine, researchers found that blood cancer patients with Covid-19 who had higher CD8 T cells, many of whom had depleted antibodies from cancer treatments, were more than 3 times likelier to survive than patients with fewer CD8 T cells.
The team studied hospitalised patients with both solid tumours and hematologic cancers admitted to hospitals to better understand the immune determinants of Covid-19 deaths.
Immune profiling of patient blood samples revealed that patients with blood cancers, in particular patients treated with anti-CD20 antibodies, had decreased B cells and antibodies compared to patients with solid cancers and patients without cancer.
Newsletter | Click to get the day’s best explainers in your inbox
Subscriber Only Stories
Additional analyses revealed that among patients with blood cancers, those with higher CD8 T cell counts had a 3.6-fold greater likelihood of survival compared to those with lower counts.
— Source: Penn Medicine News
📣 Join our Telegram channel (The Indian Express) for the latest news and updates
- The Indian Express website has been rated GREEN for its credibility and trustworthiness by Newsguard, a global service that rates news sources for their journalistic standards.